Ropinirole, a Non-Ergoline Dopamine Agonist
نویسندگان
چکیده
منابع مشابه
Ropinirole for the treatment of restless legs syndrome
Ropinirole is a non-ergoline dopamine agonist that exhibits a high affinity for D(2) and D(3) receptors but little or no affinity for D(1)-like and non-dopaminergic receptors. Symptoms of restless legs syndrome (RLS) [measured using the International Restless Legs scale and Clinical Global Impression-Global Improvement Scale scores] significantly improved with ropinirole compared with placebo i...
متن کاملEnantiomerically pure aminoindolizines: bicyclic ergoline analogues with dopamine autoreceptor activity.
The development of drugs which stimulate selectively the prejunctional dopamine receptor has become a major challenge in recent years1,2), These autoreceptor agonists decrease synthesis and release of dopamine (OA), Thus, the symptoms of schizophrenia originated from dopamine hyperactivity in the mesolimbic system should be reduced. On the other hand, it has been shown that OA autoreceptor agon...
متن کاملEYcacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre study
Objectives—Pramipexole, a non-ergot dopamine D2/D3 receptor agonist, was investigated as an add on drug in advanced parkinsonian patients with motor fluctuations to assess eYcacy, safety, and tolerance. Methods—Seventy eight patients of either sex with advanced Parkinson’s disease and treatment complications such as motor fluctuations were enrolled into a double blind, placebo controlled, rando...
متن کاملEfficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.
OBJECTIVES Pramipexole, a non-ergot dopamine D2/D3 receptor agonist, was investigated as an add on drug in advanced parkinsonian patients with motor fluctuations to assess efficacy, safety, and tolerance. METHODS Seventy eight patients of either sex with advanced Parkinson's disease and treatment complications such as motor fluctuations were enrolled into a double blind, placebo controlled, r...
متن کاملS32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
S32504 [(+)-trans-3,4,4a,5,6,10b-hexahydro-9-carbamoyl-4-propyl-2H-naphth[1,2-b]-1,4-oxazine] displayed marked affinity for cloned, human (h)D(3) receptors (pK(i), 8.1) at which, in total G-protein ([(35)S]GTPgammaS binding, guanosine-5'-O-(3-[(35)S]thio)-triphosphate), Galpha(i3) (antibody capture/scintillation proximity), and mitogen-activated protein kinase (immunoblot) activation procedures...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: CNS Drug Reviews
سال: 2006
ISSN: 1080-563X
DOI: 10.1111/j.1527-3458.2005.tb00046.x